Skip to main content
. Author manuscript; available in PMC: 2013 Jan 3.
Published in final edited form as: Cell Rep. 2012 Nov 29;2(6):1492–1497. doi: 10.1016/j.celrep.2012.11.001

Figure 2. Compound-treatment mediated changes in R6/2 mouse brain.

Figure 2

(A) AK-7 decreases the size of striatal neuronal intranuclear huntingtin aggregates. Immunodetection of intraneuronal huntingtin aggregates by using EM48 antibody (arrows) in the neostriatum of 12-week-old R6/2 mice with and without AK-7 treatment (Scale bars, 25 μm.) (B) Stereological counts of striatal intraneuronal aggregates in R6/2 mice. AK-7 treatment significantly reduced (35%) the striatal nuclear aggregate volume in R6/2 mice. (C–D)AK -7 treatment had no effect on mean aggregate count or levels of soluble mutant huntingtin Exon 1 fragments, as detected by highly sensitive HTRF method. Error bars indicate SEM, ***, P ≤ 0.001; n=8–10.